Astellas Pharma Europe Limited

At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater value by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.

Intellectual Property Rights and incentives - including Orphan Medicinal Products, Paediatric medicines
Free Trade Agreements - EU/US, EU/UK,
EU Beating Cancer Plan,
EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes,
Industrial strategy,
Competition law,
Horizon Europe,
Innovative Health Initiative (IHI),
European Medicines Agency (EMA),
European Health Data Space (EHDS)
Committee of the Regions,
Clinical Trials Regulation,
Data Protection Regulation,
Digital health,
Community code related to medicinal products for human use in mainly countries that are part of the European Union - General Pharma Legislation
Other policy areas of interest include Manufacturing, Health outcomes, Real world evidence, Pricing, reimbursement and market access to medicines, cancer, healthcare sustainability, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.

https://www.astellas.com/en/

2

1

Astellas has one person dedicated to EU policies' discussion for which the person has interactions with policymakers.

Data not provided by Register Secretariat due to GDPR

Data not provided by Register Secretariat due to GDPR

Companies & groups